

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Saul Tzipori, Ramaswamy Balakrishnan, and Arthur Donohue-Rolfe

Serial No: 10/041,958

Art Unit: 1645

Filed: January 2, 2002

Examiner: Mark Navarro

For: HUMAN NEUTRALIZING ANTIBODIES AGAINST
HEMOLYTIC UREMIC SYNDROMECommissioner of Patents
Washington, D.C. 20231PRE AMENDT/A
AJ
P#8
1-31-03

SUPPLEMENTAL PRELIMINARY AMENDMENT

Sir:

Responsive to the Interview on December 4, 2002, please amend the application,
as follows.

In the Claims

Please cancel claims 1-25. Please add new claims 26-36.

- Sub B-1
26. A dosage formulation comprising an effective amount of human or humanized monoclonal antibodies, the antibodies consisting of antibodies neutralizing Shiga like toxin II, to prevent or treat hemolytic uremic syndrome in a human.
27. The dosage formulation of claim 26, wherein the antibodies are human monoclonal antibodies.
28. The dosage formulation of claim 26, wherein the antibodies are produced by recombinant DNA methodology.
29. The dosage formulation of claim 26, wherein the antibodies are chimeric monoclonal antibodies.
- H